Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThis audio file is brought to you by 
0:00
0:00
Loading audio file, please wait.
Indianapolis-based Eli Lilly and Co. said today that it has closed its acquisition of ImClone Systems Inc., a New York-based developer of cancer drugs.
Lilly paid $70 in cash for each share of ImClone in a deal worth about $6.3 billion.
Lilly outbid New York rival Bristol-Myers Squibb Co., but analysts question whether Lilly will make enough money from the cancer drugs to make the expensive acquisition profitable.
Please enable JavaScript to view this content.